title: The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy.
abstract: BACKGROUND
  N-acetylcysteine (NAC) is reported to have potential for prevention of contrast-induced nephropathy(CIN), however, there is not enough data related to its effects on diabetic patients without nephropathy.
  
  
  METHODS
  A total of 45 diabetic patients without nephropathy undergoing a computerized tomography (CT) investigation and who would be receiving radio-opaque medication (300 mg iohexaol/100 mL) were enrolled. They were randomized to have either high-dose NAC (1200 mg) plus saline hydration (Group 1, n=25) or only saline hydration (Group 2; n=20). Serum creatinine levels were determined 72 hours post-contrast. CIN was defined as 0.3 mg/dL elevation of creatinine from baseline and/or an increment of 20% over baseline creatinine and/or 20% decrement of estimated GFR.
  
  
  RESULTS
  In Group 1, serum creatinine decreased from 0.83 to 0.79 mg/dL, whereas serum creatinine increased from 0.81 to 0.94 mg/dL in Group 2 (not significant for both groups). However there was a significant difference between the creatinine variation of two groups (p=0.031). Furthermore, the groups were analyzed according to overall incidence of CIN. The increase of serum creatinine and decrement of estimated GFR in Group 2 were significantly higher than in Group 1.
  
  
  CONCLUSIONS
  Adding NAC to saline hydration seems more beneficial than saline hydration alone in preventing contrast-induced renal function deterioration in type 2 diabetic patients without nephropathy.
authors.affiliation: Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey.
authors.forename: Fuat
authors.initials: F
authors.lastname: Sar
authors.forename: Tayyibe
authors.initials: T
authors.lastname: Saler
authors.forename: Alphan
authors.initials: A
authors.lastname: Ecebay
authors.forename: Zuhal A
authors.initials: ZA
authors.lastname: Saglam
authors.forename: Savas
authors.initials: S
authors.lastname: Ozturk
authors.forename: Rumeyza
authors.initials: R
authors.lastname: Kazancioglu
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D003287:Contrast Media; D000111:Acetylcysteine